42:, which compare the new treatment to an established one, are usually multicenter ones. In contrast, Phase I trials, which test potential toxicity of the treatment, and Phase II trials, which establish some preliminary efficacy of the tested treatment, are usually single-center trials, as they require fewer participants.
46:
increase the generalizability of the study. In many cases, efficacy will vary significantly between population groups with different genetic, environmental, and ethnic or cultural backgrounds ("demographic" factors); multicenter trials are better at evaluating these factors, by giving the opportunity for more
24:
that involves more than one independent medical institutions in enrolling and following trial participants. In multicenter trials the participant institutions follow a common treatment protocol and follow the same data collection guidelines, and there is a single coordinating center that receives,
45:
The benefits of multicenter trials also include the potential for a more heterogenous sample of participants, from different geographic locations and a wider range of population groups, treated from physicians of different backgrounds, and the ability to compare results among centers, all of which
33:
An important benefit of multicenter trials is that they permit the enrollment of a larger number of participants at a faster rate, in comparison to a single-center trial, putting to use the sources of multiple institutions. This is crucial when the anticipated benefit from a treatment will be
221:
50:. Heterogeneity in the sample means that the findings will be more generalizable. On the other hand, a more heterogeneous study population generally requires a larger sample size to detect a given difference.
253:
222:
Role of ICH GCP and
Recruitment Strategies Training of Clinical Sites Staff in Successful Patient Recruitment Rates By Marithea Goberville, Ph.D.
38:
necessary. Therefore, studies on preventive measures and therapies tend to be designed as multicenter trials. In studying novel pharmaceuticals,
545:
541:
591:
549:
537:
246:
712:
628:
493:
463:
239:
171:
136:
88:
750:
557:
595:
317:
743:
428:
226:
722:
216:
153:
686:
658:
587:
341:
772:
736:
412:
531:
777:
469:
417:
297:
128:
515:
385:
363:
332:
307:
290:
68:
666:
503:
424:
507:
394:
302:
266:
231:
473:
8:
380:
312:
39:
633:
583:
398:
327:
285:
707:
671:
563:
485:
262:
167:
132:
116:
84:
47:
163:
481:
402:
356:
351:
159:
124:
76:
34:
relatively small, or an expected outcome is likely to be uncommon, making a larger
676:
499:
454:
80:
702:
623:
575:
368:
280:
21:
766:
681:
648:
643:
152:
Bryant, J; et al. (2014). "Multicenter Trials: Rationale and
Examples".
523:
407:
717:
571:
444:
434:
35:
519:
511:
477:
439:
346:
579:
567:
613:
212:
618:
119:; et al. (1986). "Single-center versus multicenter trials".
261:
192:
190:
123:(Online ed.). Oxford Academic. pp. 23–29.
187:
764:
67:Friedman, LM; Furberg, CD; et al. (2015).
66:
247:
121:Clinical Trials: Design, Conduct and Analysis
155:Wiley StatsRef: Statistics Reference Online
254:
240:
129:10.1093/acprof:oso/9780195035681.003.0004
111:
109:
107:
546:Preventable fraction among the unexposed
542:Attributable fraction for the population
550:Preventable fraction for the population
538:Attributable fraction among the exposed
115:
60:
765:
196:
151:
104:
235:
158:(Online ed.). Wiley. p. 1.
713:Correlation does not imply causation
629:Animal testing on non-human primates
25:processes and analyzes study data.
13:
14:
789:
206:
164:10.1002/9781118445112.stat04947
75:. Springer, Cham. p. 427.
73:Fundamentals of Clinical Trials
596:Pre- and post-test probability
318:Patient and public involvement
145:
1:
53:
723:Sex as a biological variable
217:National Library of Medicine
81:10.1007/978-3-319-18539-2_21
7:
687:Intention-to-treat analysis
659:Analysis of clinical trials
588:Specificity and sensitivity
342:Randomized controlled trial
28:
10:
794:
18:multicenter research trial
731:
696:Interpretation of results
695:
657:
606:
556:
530:
492:
462:
453:
429:Nested case–control study
379:
326:
273:
298:Academic clinical trials
516:Relative risk reduction
364:Adaptive clinical trial
308:Evidence-based medicine
291:Adaptive clinical trial
504:Number needed to treat
227:IBPA Publications 2005
508:Number needed to harm
395:Cross-sectional study
347:Scientific experiment
303:Clinical study design
474:Cumulative incidence
69:"Multicenter Trials"
381:Observational study
313:Real world evidence
267:experimental design
667:Risk–benefit ratio
634:First-in-man study
584:Case fatality rate
425:Case–control study
399:Longitudinal study
213:ClinicalTrials.gov
773:Clinical research
760:
759:
708:Survivorship bias
672:Systematic review
639:Multicenter trial
602:
601:
592:Likelihood-ratios
564:Clinical endpoint
532:Population impact
486:Period prevalence
263:Clinical research
48:subgroup analyses
785:
607:Trial/test types
482:Point prevalence
460:
459:
403:Ecological study
386:EBM II-2 to II-3
357:Open-label trial
352:Blind experiment
328:Controlled study
256:
249:
242:
233:
232:
200:
194:
185:
184:
182:
180:
149:
143:
142:
113:
102:
101:
99:
97:
64:
40:Phase III trials
793:
792:
788:
787:
786:
784:
783:
782:
778:Clinical trials
763:
762:
761:
756:
727:
691:
653:
598:
552:
526:
500:Risk difference
488:
449:
383:
375:
330:
322:
286:Trial protocols
269:
260:
209:
204:
203:
195:
188:
178:
176:
174:
150:
146:
139:
114:
105:
95:
93:
91:
65:
61:
56:
31:
12:
11:
5:
791:
781:
780:
775:
758:
757:
755:
754:
751:List of topics
747:
740:
732:
729:
728:
726:
725:
720:
715:
710:
705:
703:Selection bias
699:
697:
693:
692:
690:
689:
684:
679:
674:
669:
663:
661:
655:
654:
652:
651:
646:
641:
636:
631:
626:
624:Animal testing
621:
616:
610:
608:
604:
603:
600:
599:
576:Mortality rate
562:
560:
554:
553:
536:
534:
528:
527:
498:
496:
490:
489:
468:
466:
457:
451:
450:
448:
447:
442:
437:
432:
422:
421:
420:
415:
405:
391:
389:
377:
376:
374:
373:
372:
371:
369:Platform trial
361:
360:
359:
354:
349:
338:
336:
324:
323:
321:
320:
315:
310:
305:
300:
295:
294:
293:
288:
281:Clinical trial
277:
275:
271:
270:
259:
258:
251:
244:
236:
230:
229:
224:
219:
208:
207:External links
205:
202:
201:
186:
172:
144:
137:
103:
89:
58:
57:
55:
52:
30:
27:
22:clinical trial
9:
6:
4:
3:
2:
790:
779:
776:
774:
771:
770:
768:
753:
752:
748:
746:
745:
741:
739:
738:
734:
733:
730:
724:
721:
719:
716:
714:
711:
709:
706:
704:
701:
700:
698:
694:
688:
685:
683:
682:Meta-analysis
680:
678:
675:
673:
670:
668:
665:
664:
662:
660:
656:
650:
649:Vaccine trial
647:
645:
644:Seeding trial
642:
640:
637:
635:
632:
630:
627:
625:
622:
620:
617:
615:
612:
611:
609:
605:
597:
593:
589:
585:
581:
577:
573:
569:
565:
561:
559:
555:
551:
547:
543:
539:
535:
533:
529:
525:
521:
517:
513:
509:
505:
501:
497:
495:
491:
487:
483:
479:
475:
471:
467:
465:
461:
458:
456:
452:
446:
443:
441:
438:
436:
433:
430:
426:
423:
419:
416:
414:
413:Retrospective
411:
410:
409:
406:
404:
400:
396:
393:
392:
390:
387:
382:
378:
370:
367:
366:
365:
362:
358:
355:
353:
350:
348:
345:
344:
343:
340:
339:
337:
334:
333:EBM I to II-1
329:
325:
319:
316:
314:
311:
309:
306:
304:
301:
299:
296:
292:
289:
287:
284:
283:
282:
279:
278:
276:
272:
268:
264:
257:
252:
250:
245:
243:
238:
237:
234:
228:
225:
223:
220:
218:
214:
211:
210:
198:
193:
191:
175:
173:9781118445112
169:
165:
161:
157:
156:
148:
140:
138:9780199864478
134:
130:
126:
122:
118:
112:
110:
108:
92:
90:9783319185392
86:
82:
78:
74:
70:
63:
59:
51:
49:
43:
41:
37:
26:
23:
19:
749:
742:
735:
638:
524:Hazard ratio
408:Cohort study
199:, p. 3.
177:. Retrieved
154:
147:
120:
94:. Retrieved
72:
62:
44:
32:
17:
15:
718:Null result
677:Replication
572:Infectivity
494:Association
445:Case report
435:Case series
418:Prospective
197:Bryant 2014
179:12 February
117:Meinert, CL
96:12 February
36:sample size
767:Categories
520:Odds ratio
512:Risk ratio
478:Prevalence
464:Occurrence
440:Case study
54:References
580:Morbidity
568:Virulence
470:Incidence
744:Glossary
737:Category
614:In vitro
455:Measures
274:Overview
215:from US
29:Benefits
619:In vivo
170:
135:
87:
558:Other
20:is a
397:vs.
265:and
181:2024
168:ISBN
133:ISBN
98:2024
85:ISBN
160:doi
125:doi
77:doi
769::
594:,
590:,
586:,
582:,
578:,
574:,
570:,
566:,
548:,
544:,
540:,
522:,
518:,
514:,
510:,
506:,
502:,
484:,
480:,
476:,
472:,
401:,
189:^
166:.
131:.
106:^
83:.
71:.
16:A
431:)
427:(
388:)
384:(
335:)
331:(
255:e
248:t
241:v
183:.
162::
141:.
127::
100:.
79::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.